UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading symbol(s) Name of each exchange on which registered Ordinary shares, par value NIS 0.02 per share EVGN Nasdaq Stock Market LLC FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 1 ...

Evogene Ltd. (NASDAQ:EVGN) Q3 2021 Earnings Conference Call November 17, 2021 9:00 AM ET Â Company Participants Ofer Haviv - President, Chief Executive Officer Arnon Heyman - Chief Executive Officer, Canonic Dorit Kreiner - Chief Financial Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Nathan Weinstein - Aegis Capital Brett Reiss - Janney Montgomery Scott Brian Wright - Roth Capital Partners Operator Ladies and gentlemen, thank you for standing by. Welcome to EvogeneÂ's third quarte ...

| --- | --- | --- | --- | |-------|-------|-------|-------| | | | | | | | | | | Forward Looking Statement This presentation contains "forward-looking statements" relating to future events, and Evogene Ltd (the "Company"), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 19 ...

Financial Data and Key Metrics Changes - Evogene reported consolidated cash of approximately $65.4 million as of June 30, 2021, with a cash usage of approximately $11.3 million in the first half of 2021, and $5.7 million in the second quarter [45][46] - Revenues for the second quarter of 2021 were $0.1 million, down from $0.3 million in the same period the previous year [49] - R&D expenses increased to $5.0 million in Q2 2021 from $3.9 million in Q2 2020, attributed to product development activities [50] - Operating loss for Q2 2021 was $7.4 million compared to $5.2 million in Q2 2020 [51] Business Line Data and Key Metrics Changes - Biomica is preparing for its first-in-man proof-of-concept study in immuno-oncology and reported significant pre-clinical data for its candidate BMC128 [27][28] - Canonic is establishing its production and marketing infrastructure for medical cannabis products, with plans for a product launch in Israel in 2022 [31][32] - AgPlenus is making progress in collaboration with Corteva to develop novel herbicides and has achieved positive results in its internal herbicide program [35][36] - Lavie Bio is advancing its product pipeline with a focus on biostimulants and bio fungicides, expecting to launch its lead biostimulant LAV211 in 2022 [38][40] Market Data and Key Metrics Changes - The medical cannabis market in Israel is growing rapidly, with government approval for cannabis companies to export products, opening new markets for Canonic [87] - The market for innovative life-science products is characterized by high failure rates and long commercialization timelines, but Evogene's technology aims to mitigate these risks [21][22] Company Strategy and Development Direction - Evogene's strategy focuses on unlocking the value of its subsidiaries by potentially turning them into public companies, allowing for independent valuations [24][25] - The company aims to utilize advanced computational biology to enhance product development and reduce time-to-market [14][20] - The vision is to change how life science companies develop products, increasing success probabilities while reducing costs [13] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the advancements of subsidiaries towards commercialization and the potential for significant market opportunities [61][62] - The company is cautious about cash burn rates and aims to ensure that funding aligns with strategic goals [97][98] Other Important Information - The company has a strong financial position with no bank debt and is exploring ways to facilitate independent valuations of its subsidiaries [45][49] - The transition in leadership with Sarit Firon as the new Chairperson is expected to bring new energy and direction to the company [9][10] Q&A Session Summary Question: What are the initial market opportunities for the upcoming products? - Management indicated that they are in discussions with local distributors and expect significant revenue from the second year of product launches [54][56] Question: Why is the company considering turning subsidiaries into public companies now? - The management believes that several subsidiaries are advancing towards commercialization and that independent valuations will benefit shareholders [60][62] Question: How does the company view the potential for additional product pipelines beyond the main programs? - Management confirmed that each subsidiary has a promising product pipeline beyond what has been disclosed, and they are exploring additional opportunities [66][68] Question: What is the expected cash burn for next year? - Management expects cash burn to be managed carefully, with potential collaborations providing funding for ongoing activities [99][100]

Evogene Ltd. (NASDAQ:EVGN) Q1 2021 Results Conference Call May 26, 2021 9:00 AM ET Company Participants Ofer Haviv - Chief Executive Officer Arnon Heyman - CEO Canonic Dorit Kreiner - Chief Financial Officer Ido Dor - CEO, Lavie Bio Conference Call Participants Kristen Kluska - Cantor Fitzgerald Brett Reiss - Janney Montgomery Operator Ladies and gentlemen, thank you for standing by. Welcome to Evogene's First Quarter 2021 Results Conference Call. All participants are present in listen-only mode. Following ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commissi ...

Evogene's Vision and Technology - Evogene aims to revolutionize life-science product discovery and development using computational biology technologies[5, 75] - The company utilizes a Computational Predictive Biology (CPB) platform, incorporating scientific understanding, big data, and AI[12, 75] - The CPB platform has three engines: MicroBoost AI (microbes), ChemPass AI (small molecules), and GeneRator AI (genetic elements)[75] Business Model and Subsidiaries - Evogene employs a dual business model: product development through collaborations and through subsidiaries[19, 22, 76] - The company has four main subsidiaries: Biomica (human microbiome therapeutics), Canonic (medical cannabis), AgPlenus (ag-chemicals), and Lavie Bio (ag-biologicals)[47, 76] - Evogene holds 90% of Biomica, 100% of Canonic, 98% of AgPlenus, and 72% of Lavie Bio[47] Subsidiary Pipeline Highlights - Biomica's immuno-oncology program is in the pre-clinical stage, targeting a market expected to reach $243 billion by 2026[50] - Canonic is developing MetaYield products for the medical cannabis market, which is expected to reach $25.6 billion by 2024[57] - AgPlenus has a novel MoA herbicide in the 'Lead' stage, targeting a herbicide market expected to reach $34 billion by 2022[61, 63] - Lavie Bio's bio-insecticides addressable market size is $1.5 billion[67] Financial Status - As of December 31, 2020, Evogene had a consolidated cash position of approximately $48.2 million, with around $13 million allocated to Lavie Bio[91] - The estimated net cash usage for 2021, excluding Lavie Bio, is projected to be between $20 million and $22 million[91]

Evogene Ltd. (NASDAQ:EVGN) Q3 2020 Earnings Conference Call November 18, 2020 9:00 AM ET Company Participants Ofer Haviv - Chief Executive Officer Elran Haber - CEO of Biomica Dorit Kreiner - Chief Financial Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Geoff Gilbert - Inukshuk Investment Operator Ladies and gentlemen, thank you for standing by. Welcome to EvogeneÂ's Third Quarter 2020 Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded ...

Evogene Ltd. (NASDAQ:EVGN) Q2 2020 Earnings Conference Call August 5, 2020 9:00 AM ET Company Participants Ofer Haviv - Chief Executive Officer Dorit Kreiner - Chief Financial Officer Gadi Ben Nissim - Executive Vice President, Corporate Development Operator Ladies and gentlemen, thank you for standing by. Welcome to EvogeneÂ's Second Quarter 2020 Results Conference Call. All participants are present in a listen-only mode. Following managementÂ's formal presentation, instructions will be given for the quest ...

| --- | --- | --- | --- | |-------|-------|-------|-------| | | | | | | | | | | | | | | | Forward Looking Statement This presentation contains "forward-looking statements" relating to future events, and we may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting Evogene Ltd. or its subsidiaries (collectively, "Evogene" or "we"), that are considered "forward-looking statements" as defined in the U. ...